Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy caucasian volunteers

Chemotherapy

Volumn 48, Issue 3, 2002, Pages 116-121

  Mignot, Alain ^a   Guillaume, Michel ^a   Brault, Muriel ^a   Gualano, Virginie ^a   Millérioux, Laurette ^a   Göhler, Karin ^b   Stahlberg, Hans Juergen ^b  

^a Aster Cephac   (France)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERANCE; DRUG URINE LEVEL; FECES ANALYSIS; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; URINARY EXCRETION; CHEMISTRY; CLINICAL TRIAL; DRUG ADMINISTRATION; FECES; HALF LIFE TIME; ORAL DRUG ADMINISTRATION; URINE;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE; CAUCASOID RACE; DRUG ADMINISTRATION SCHEDULE; FECES; HALF-LIFE; HUMAN; MALE; ANTI-INFECTIVE AGENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLUOROQUINOLONES; HUMANS;

EID: 0035986259     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064915     Document Type: Article

References (12)

1. Introduction and historical background
2. Comparative in-vitro activities of the new quinolone Bay y 3118, ciprofloxacin, sparfloxacin, Tosufloxacin, CI-960 and CI-990
3. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
4. The activity of the methylpiperazinyl fluoro-quinolone CG 5501: A comparison with other quinolones
5. High performance liquid chromatography determination of gatifloxacin, a new quinolone, in biological fluids
6. The bactericidal activity of gatifloxacin in plasma and urine
7. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans
8. Single dose pharmacokinetics of theR- andS-enantiomers of gatifloxacin in volunteers
9. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men
10. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and phar-macodynamics of antimicrobials
11. Pharmacokinetics and pharmacodynamics of oral gatifloxacin in patients with acute bacterial exacerbations of chronic bronchitis
12. Mathematical examination of dual individualization principles. I. Relationship between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin and tobramycin